Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Breast Neoplasms 103Lymphoma 68Lymphoma, Large B-Cell, Diffuse 49Precursor Cell Lymphoblastic Leukemia-Lymphoma 41Sarcoma 33Lymphoma, Non-Hodgkin 29Hodgkin Disease 28Leukemia 23Burkitt Lymphoma 22Neoplasms 19Lymphoma, Mantle-Cell 18Triple Negative Breast Neoplasms 15Multiple Myeloma 15Lymphoma, Follicular 15Lymphoma, B-Cell 14Lymphoma, Large-Cell, Anaplastic 12Carcinoma, Hepatocellular 12Breast Neoplasms, Male 11Neuroblastoma 10Recurrence 9Ovarian Neoplasms 9Neoplasm Metastasis 9Inflammatory Breast Neoplasms 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, T-Cell, Peripheral 8Lymphoma, T-Cell 8Osteosarcoma 7Fallopian Tube Neoplasms 7Urinary Bladder Neoplasms 6Liposarcoma 6

Interventions

Rituximab 4Cyclophosphamide 4ponatinib 2Vorinostat 2Vincristine 2Prednisone 2Etoposide 2Doxorubicin 2Brentuximab Vedotin 2Bortezomib 2tetulomab tetraxetan lu-177 1pembrolizumab 1ibrutinib 1ibritumomab tiuxetan 1fludarabine 1durvalumab 1cobomarsen 1acalabrutinib 1Melphalan 1Lutetium 1Lenalidomide 1KW-2478 1Imatinib Mesylate 1Ifosfamide 1Hsp90 inhibitor KU757 1Cytarabine 1Carmustine 1Carboplatin 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Immune System Diseases × Doxorubicin × Clear all
NCT02855359 2019-03-11

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

Seagen Inc.

Phase 2 Terminated
24 enrolled 10 charts
Lymphoid

Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00365274 2014-06-02

SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma

National Cancer Institute (NCI)

Phase 2 Terminated
6 enrolled 3 charts
Lymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡